Epcoritamab is indicated for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, including diffuse large B-cell lymphoma arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy.

Nov 17, 2023 · What is epcoritamab? Epcoritamab is used to treat certain types of lymphoma (a cancer of the lymphatic system) in adults whose cancer has returned or did not respond to another treatment and who have received at least two previous cancer treatments. Epcoritamab may also be used for purposes not listed in this medication guide.

Dec 22, 2022 · Epcoritamab is a subcutaneously administered CD3xCD20 T-cell–engaging, bispecific antibody that activates T cells, directing them to kill malignant CD20 + B cells. Single-agent epcoritamab previously demonstrated potent antitumor activity in dose escalation across B-cell non-Hodgkin lymphoma subtypes.

Sep 25, 2024 · Primary results (median follow-up, 10.7 months) from the pivotal EPCORE ® NHL-1 study in relapsed or refractory (R/R) large B-cell lymphoma (LBCL) demonstrated deep, durable responses with...

Apr 20, 2023 · Purpose: Epcoritamab is a subcutaneously administered CD3xCD20 T-cell-engaging, bispecific antibody that activates T cells, directing them to kill malignant CD20 + B cells. Single-agent epcoritamab previously demonstrated potent antitumor activity in dose escalation across B-cell non-Hodgkin lymphoma subtypes.

On June 26, 2024, the Food and Drug Administration granted accelerated approval to epcoritamab-bysp (Epkinly, Genmab US, Inc.), a bispecific CD20-directed CD3 T-cell engager, for adult patients...

Epcoritamab is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. 4,6

Jul 1, 2024 · Epkinly (epcoritamab-bysp) is used for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma. Includes Epkinly side effects, interactions and indications.

Epcoritamab-bysp is a type of targeted therapy drug called a bispecific T-cell engager (BiTE). FDA label information for this drug is available at DailyMed. Epcoritamab-bysp is approved to treat adults with: Diffuse large B-cell lymphoma (DLBCL) or …

The active substance in Tepkinly, epcoritamab, is an antibody (a type of protein) which is described as ‘bispecific’ because it recognises and attaches to two targets simultaneously: CD20, a protein that is present on the surface of B cells (including the cancer cells), and CD3, a protein found on the surface of healthy T cells (cells in ...